Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Metformin reduces Afib after ablation

Written by | 16 Nov 2025

Obese or overweight non-diabetic adults with atrial fibrillation (Afib) who take the diabetes medication metformin after a catheter ablation are more likely to remain free of AFib for… read more.

Coffee might benefit patients treated for atrial fibrillation

Written by | 15 Nov 2025

Adults treated for atrial fibrillation (AFib/AF) who consume a daily cup of coffee are 39% less likely to have an irregular heart rhythm episode compared to those who… read more.

New clinical study data from the Volt CE Mark Study showcase long-term, sustained benefits of Volt PFA System for patients with AFib – Abbott

Written by | 6 Aug 2025

Abbott announced new data from its Volt CE Mark Study that show strong safety and efficacy out to 12 months for patients receiving pulsed field ablation (PFA) therapy… read more.

Affera pulsed field ablation technologies continue to demonstrate promising evidence for atrial fibrillation patients – Medtronic

Written by | 1 Jun 2025

Medtronic plc announced positive clinical outcomes from two studies in atrial fibrillation (AFib) patients treated with the Affera family of technologies, including the next-generation Sphere-360 single-shot pulsed field… read more.

Second phase of ADVANTAGE AF study of FARAPULSE Pulsed Field Ablation System meets primary safety and efficacy endpoints – Boston Scientific

Written by | 4 May 2025

Boston Scientific announced positive 12-month primary endpoint results from the second phase of the ADVANTAGE AF clinical trial evaluating the use of the Farapulse Pulsed Field Ablation (PFA)… read more.

Pivotal 12-month effectiveness and safety data from SmartfIRE study presented at 2025 EHRA Congress – Johnson & Johnson / MedTech

Written by | 24 Apr 2025

Johnson & Johnson MedTech announced 12-month results from the SmartfIRE study, presented as a late-breaking presentation at the annual meeting of the European Heart Rhythm Association (EHRA) in… read more.

CE Mark approved in Europe for the Volt PFA system to treat patients with atrial fibrillation – Abbott

Written by | 4 Apr 2025

Abbott announced it has received CE Mark in Europe for the Volt PFA System to treat patients battling atrial fibrillation (AFib). With the earlier-than-expected CE Mark, Abbott has… read more.

Risk of dementia increases with mid-life AF diagnosis

Written by | 3 Apr 2025

Researchers report a significantly increased risk of dementia in patients diagnosed with atrial fibrillation (AF) in midlife, and a significantly increased risk of early-onset dementia (EOD) as well…. read more.

Bleeding risks vary among atrial fibrillation treatments

Written by | 11 Feb 2025

A meta-analysis evaluating bleeding risks among atrial fibrillation (AF) patients treated with therapeutic-dose non-vitamin K oral anticoagulants (NOACs) and single antiplatelet therapy (aspirin) indicates that rates of major… read more.

240-year-old drug could save UK National Health Service £100 million a year treating common heart rhythm disorder

Written by | 7 Feb 2025

A 240-year-old drug called digoxin could save the National Health Service (NHS) at least £100 million each year when treating older patients with atrial fibrillation and heart failure. … read more.

Late-breaking data presented at AF Symposium 2025 highlight key Boston Scientific therapies for management of patients with atrial fibrillation

Written by | 21 Jan 2025

Boston Scientific Corporation (announced data supporting the use of the FARAPULSE Pulsed Field Ablation (PFA) System  during a late-breaking science session at AF Symposium 2025. Currently, the FARAPULSE… read more.

FDA approval of Varipulse Platform to treat refractory paroxysmal atrial fibrillation – J&J Med Tech

Written by | 13 Nov 2024

Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, announced the FDA approval of the Varipulse  Platform for the treatment of drug refractory paroxysmal Atrial Fibrillation… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.